Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort

An effective vaccine against the dengue virus (DENV) should induce a balanced, long-lasting antibody (Ab) response against all four viral serotypes. The burst of plasmablasts in the peripheral blood after vaccination may reflect enriched vaccine-specific Ab secreting cells. Here we characterize the...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 908398
Main Authors Silveira, Cássia G T, Magnani, Diogo M, Costa, Priscilla R, Avelino-Silva, Vivian I, Ricciardi, Michael J, Timenetsky, Maria do Carmo S T, Goulart, Raphaella, Correia, Carolina A, Marmorato, Mariana P, Ferrari, Lilian, Nakagawa, Zelinda B, Tomiyama, Claudia, Tomiyama, Helena, Kalil, Jorge, Palacios, Ricardo, Precioso, Alexander R, Watkins, David I, Kallás, Esper G
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.06.2022
Subjects
Antibodies, Viral
Brazil
dengue
dengue infection
dengue vaccine
Dengue Vaccines
Dengue Virus
Humans
humoral response
Immunology
plasmablast
Vaccines, Attenuated
Brazil
plasmablast
dengue vaccine
dengue
dengue infection
humoral response
Online AccessGet full text

Cover

More Information
Summary:An effective vaccine against the dengue virus (DENV) should induce a balanced, long-lasting antibody (Ab) response against all four viral serotypes. The burst of plasmablasts in the peripheral blood after vaccination may reflect enriched vaccine-specific Ab secreting cells. Here we characterize the acute plasmablast responses from naïve and DENV-exposed individuals following immunization with the live attenuated tetravalent (LAT) Butantan DENV vaccine (Butantan-DV). The frequency of circulating plasmablasts was determined by flow cytometric analysis of fresh whole blood specimens collected from 40 participants enrolled in the Phase II Butantan-DV clinical trial (NCT01696422) before and after (days 6, 12, 15 and 22) vaccination. We observed a peak in the number of circulating plasmablast at day 15 after vaccination in both the DENV naïve and the DENV-exposed vaccinees. DENV-exposed vaccinees experienced a significantly higher plasmablast expansion. In the DENV-naïve vaccinees, plasmablasts persisted for approximately three weeks longer than among DENV-exposed volunteers. Our findings indicate that the Butantan-DV can induce plasmablast responses in both DENV-naïve and DENV-exposed individuals and demonstrate the influence of pre-existing DENV immunity on Butantan DV-induced B-cell responses.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: James Drew Brien, Saint Louis University, United States
Reviewed by: Justin Richner, University of Illinois at Chicago, United States; Carlos Roberto Prudencio, Adolfo Lutz Institute, Brazl; Ellen Young, University of North Carolina at Chapel Hill, United States
Present Address: Diogo M. Magnani, MassBiologics of University of Massachusetts, Medical School, Boston, MA, United States; Priscilla R. Costa, MassBiologics of University of Massachusetts, Medical School, Boston, MA, United States; David I. Watkins, Department of Pathology, The George Washington University, Washington, DC, United States; Michael J. Ricciardi, Department of Pathology, The George Washington University, Washington, DC, United States
These authors have contributed equally to this work
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.908398